Zelboraf Oral Tablet 240Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Zelboraf: Oral tablet (240mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

VEMURAFENIB (Vem ue RAF e nib) is a chemotherapy drug. It targets specific cancer cells and stops the cancer cells from growing. It is used to treat certain types of melanoma skin cancer.

In-Depth Information

Zelboraf 240mg Tablet

NDC: 502420090
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Malignant Melanoma

Storage Information
Store in original container
Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F
Zelboraf 240mg Tablet

Reported Side Effects for Zelboraf 240mg Tablet

Rash Of Red Skin Bumps Incidence:
<10.0%*
Severity: SEVERE
Onset: DELAYED
Lightheadedness Incidence:
<10.0%*
Severity: MILD
Onset: EARLY
Chills Incidence:
<5.0%*
Severity: MILD
Onset: RAPID
Drug-Induced Acne Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Secondary Malignancy Incidence:
<24.0%*
Severity: MODERATE
Onset: DELAYED
Vomiting Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Inflamed Blood Vessels Incidence:
<10.0%*
Severity: SEVERE
Onset: DELAYED
Retinal Detachment Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Nerve Pain Incidence:
<10.0%*
Severity: MODERATE
Onset: DELAYED
Upset Stomach Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Weight Loss Incidence:
<10.0%*
Severity: MILD
Onset: DELAYED
Visual Impairment Incidence:
<4.0%*
Severity: SEVERE
Onset: EARLY
Lyell'S Syndrome Incidence:
<10.0%*
Severity: SEVERE
Onset: DELAYED
Kidney Failure Incidence:
<0.4%*
Severity: SEVERE
Onset: DELAYED
Skin Rash Incidence:
<17.0%*
Severity: SEVERE
Onset: EARLY
Hand And Foot Syndrome Incidence:
<10.0%*
Severity: MODERATE
Onset: DELAYED
Muscle Paralysis Incidence:
<10.0%*
Severity: SEVERE
Onset: DELAYED
Low Lymphocytes Incidence:
<8.0%*
Severity: SEVERE
Onset: DELAYED
Anemia Incidence:
<3.3%*
Severity: SEVERE
Onset: DELAYED
Irregular Heart Beat Incidence:
<10.0%*
Severity: SEVERE
Onset: EARLY
Loose Stools Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Inflamed Hair Follicles Incidence:
<10.0%*
Severity: MILD
Onset: DELAYED
Heart Failure Incidence:
<19.0%*
Severity: SEVERE
Onset: DELAYED
High Potassium Level Incidence:
<0.4%*
Severity: SEVERE
Onset: DELAYED
Low Calcium Levels Incidence:
<1.7%*
Severity: SEVERE
Onset: DELAYED
Low Potassium Levels Incidence:
<3.3%*
Severity: SEVERE
Onset: DELAYED
Low Blood Sodium Levels Incidence:
<2.1%*
Severity: SEVERE
Onset: DELAYED
Low Phosphate Level Incidence:
<6.0%*
Severity: SEVERE
Onset: DELAYED
Intestinal Bleeding Incidence:
<1.2%*
Severity: SEVERE
Onset: DELAYED
Bleeding Incidence:
<0.8%*
Severity: SEVERE
Onset: EARLY
Eye Inflammation Incidence:
<10.0%*
Severity: SEVERE
Onset: DELAYED
Low Platelet Count Incidence:
<10.0%*
Severity: MODERATE
Onset: DELAYED
Blood In The Urine Incidence:
<0.8%*
Severity: MODERATE
Onset: DELAYED
Mouth Ulcers Incidence:
<8.0%*
Severity: MODERATE
Onset: DELAYED
Stevens-Johnson Syndrome Incidence:
<10.0%*
Severity: SEVERE
Onset: DELAYED
Low Albumin In Blood Incidence:
<0.4%*
Severity: SEVERE
Onset: DELAYED
Lung Inflammation Incidence:
<10.0%*
Severity: MODERATE
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
0.9-17.0%*
Severity: SEVERE
Onset: DELAYED
High Bilirubin Level Incidence:
1.2-1.9%*
Severity: MODERATE
Onset: DELAYED
Inflamed Iris (Eye) Incidence:
1.5%*
Severity: MODERATE
Onset: DELAYED
Blurred Vision Incidence:
1.5%*
Severity: MODERATE
Onset: EARLY
Light Sensitivity Incidence:
1.8%*
Severity: MODERATE
Onset: EARLY
Weakness Incidence:
2.0-11.0%*
Severity: MILD
Onset: DELAYED
High Blood Pressure Incidence:
2.0%*
Severity: SEVERE
Onset: EARLY
Back Pain Incidence:
8.0-11.0%*
Severity: MILD
Onset: DELAYED
Cough Incidence:
8.0-12.0%*
Severity: MILD
Onset: DELAYED
Muscle And/Or Bone Pain Incidence:
8.0-11.0%*
Severity: MILD
Onset: EARLY
Skin Redness Incidence:
8.0-14.0%*
Severity: MODERATE
Onset: EARLY
Rash With Pustules Incidence:
9.0-21.0%*
Severity: MILD
Onset: EARLY
Keratopathy Incidence:
10.0-14.0%*
Severity: MODERATE
Onset: DELAYED
Photosensitivity Incidence:
10.0-49.0%*
Severity: MILD
Onset: DELAYED
Metallic Taste Incidence:
11.0-14.0%*
Severity: MILD
Onset: EARLY
Constipation Incidence:
12.0-16.0%*
Severity: MODERATE
Onset: DELAYED
Muscle Pain Incidence:
13.0-24.0%*
Severity: MILD
Onset: EARLY
Dry Skin Incidence:
16.0-19.0%*
Severity: MILD
Onset: DELAYED
Fever Incidence:
17.0-23.0%*
Severity: MILD
Onset: EARLY
Fluid Retention Incidence:
17.0-23.0%*
Severity: MODERATE
Onset: DELAYED
Headache Incidence:
23.0-27.0%*
Severity: MILD
Onset: EARLY
Itching Incidence:
23.0-30.0%*
Severity: MILD
Onset: RAPID
Hyperkeratosis Incidence:
24.0-28.0%*
Severity: MILD
Onset: DELAYED
Hair Loss Incidence:
36.0-45.0%*
Severity: MILD
Onset: DELAYED
Tired Incidence:
38.0-54.0%*
Severity: MILD
Onset: EARLY
Joint Pain Incidence:
53.0-67.0%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Zelboraf 240mg Tablet

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Major Lifestyle Interaction
Grapefruit juice and Zelboraf 240mg Tablet(Vemurafenib)
Grapefruit juice and Vemurafenib(Vemurafenib)
If you drink grapefruit juice, talk to your health care professional. Taking these drugs together may increase the levels of vemurafenib in your body and increase the risk of vemurafenib side effects such as skin rash, liver problems, and change in heart beat or heart rhythms.
Major Lifestyle Interaction
Alcohol and Zelboraf 240mg Tablet(Vemurafenib)
Alcohol and Vemurafenib(Vemurafenib)
Do not use Ethanol (alcohol) and Vemurafenib without talking to your healthcare provider. Ethanol may lower blood concentrations of Vemurafenib and decrease the effectiveness of Vemurafenib.
Minor Lifestyle Interaction
Caffeine-containing Foods/Beverages and Zelboraf 240mg Tablet(Vemurafenib)
Caffeine-containing Foods/Beverages and Vemurafenib(Vemurafenib)
Side effects from Caffeine may get worse if you take Vemurafenib. Too much Caffeine can cause effects like nausea, nervousness, or sleeplessness. You may need to limit your Caffeine intake. Common foods and beverages containing caffeine include coffee, teas, colas and chocolate. Many non-prescription drugs and diet aids may also contain caffeine.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Zelboraf

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5